Recent advances in understanding chemotherapy-induced peripheral neuropathy

Recent advances in understanding... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/9-177" }, "headline": "Recent advances in understanding chemotherapy-induced peripheral neuropathy", "datePublished": "2020-03-11T10:54:32", "dateModified": "2020-03-11T10:54:32", "author": [ { "@type": "Person", "name": "Richard Gordon-Williams" }, { "@type": "Person", "name": "Paul Farquhar-Smith" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/9-177", "name": "Recent advances in understanding chemotherapy-induced peripheral neuropathy" } } ] } Home Browse Recent advances in understanding chemotherapy-induced peripheral neuropathy ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Gordon-Williams R and Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved] . F1000Research 2020, 9 (F1000 Faculty Rev):177 ( https://doi.org/10.12688/f1000research.21625.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Review Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved] Richard Gordon-Williams https://orcid.org/0000-0003-1742-3619 1 , Paul Farquhar-Smith 1 Richard Gordon-Williams https://orcid.org/0000-0003-1742-3619 1 , Paul Farquhar-Smith 1 PUBLISHED 11 Mar 2020 Author details Author details 1 Department of Pain Medicine, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK Richard Gordon-Williams Roles: Writing – Original Draft Preparation, Writing – Review & Editing Paul Farquhar-Smith Roles: Conceptualization, Supervision, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of pain and poor quality of life for those undergoing treatment for cancer and those surviving cancer. Many advances have been made in the pre-clinical science; despite this, these findings have not been translated into novel preventative measures and treatments for CIPN. This review aims to give an update on the pre-clinical science, preventative measures, assessment and treatment of CIPN. READ ALL READ LESS Keywords Chemotherapy, Neuropathy, Pain, Survivorship Corresponding Author(s) Richard Gordon-Williams ( [email protected] ) Close Corresponding author: Richard Gordon-Williams Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2020 Gordon-Williams R and Farquhar-Smith P. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Gordon-Williams R and Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved] . F1000Research 2020, 9 (F1000 Faculty Rev):177 ( https://doi.org/10.12688/f1000research.21625.1 ) First published: 11 Mar 2020, 9 (F1000 Faculty Rev):177 ( https://doi.org/10.12688/f1000research.21625.1 ) Latest published: 11 Mar 2020, 9 (F1000 Faculty Rev):177 ( https://doi.org/10.12688/f1000research.21625.1 ) Introduction The last decade has heralded improvements in cancer survival 1 . However, persistent effects following the treatment of cancer can lead to pain and an impaired quality of life long after treatment has finished or cancer has been cured 2 . Chemotherapy-induced peripheral neuropathy (CIPN) is one of those effects that can lead to a continuing symptom burden after treatment 3 . CIPN is characterised by the classic “glove and stocking” distribution of symptoms. After chemotherapy, 68% of patients have painful neuropathy at 6 months, improving to 33% at 1 year 4 . Although different chemotherapies have variable characteristics, symptoms tend to be predominantly sensory. Sensory toxicity is the predominant feature as dorsal root ganglion (DRG), containing the sensory cell bodies, have a fenestrated endothelium that is more permeable than that found in the spinal cord, where the motor cell bodies lie. Sensory features are characterised by so-called “positive” and “negative” symptoms. “Negative” symptoms include numbness, loss of vibration sense, proprioception and deep tendon reflexes, whereas paraesthesia, dysaesthesia, and cold and mechanical hypersensitivity are referred to as “positive” symptoms. The development of pain is also a common reason for dose reduction 4 , 5 , which may have implications for oncological outcome 6 . The situation is further complicated by the effect of “coasting”, whereby the development of pain is delayed until after stopping the chemotherapy. Despite advances in cancer treatment and survival, we still have much to learn about CIPN. It is important to recognise that CIPN is a heterogeneous population; it may be acute, such as the neuropathy commonly experienced with oxaliplatin, or chronic, lasting well beyond the end of treatment. Although there may be some overlap in features, it is likely that the underlying pathophysiology, clinical features and therefore its management differ substantially. Furthermore, not all CIPN is considered painful. This review will focus on the mechanisms but also deliberate on clinical features and treatment of chronic painful CIPN. Animal models Animal models of CIPN have increased understanding of the pathophysiology of CIPN, yet a recent meta-analysis highlights problems with the current models and may help deliver more robust and valid models 7 . For example, how do studies assessing short-term pain behaviours in animals without tumour burden model chronic CIPN? Pre-clinical studies often focus on the gain-of-function symptoms rather than the loss of function (for example, numbness) more common with chronic CIPN. Misrepresentation of the sexes is evident; 83% of animals used were male. Newer models have addressed some of these criticisms. Griffiths et al . describe a paclitaxel model of CIPN for 28 days with ethologically relevant behavioural tests that better mirror the clinical picture 8 . Non-human primate models may be more similar to the human condition 9 but, owing to ethical and pragmatic issues, are not a feasible alternative to rodents. Mechanisms The main classes of chemotherapeutics that cause neuropathy include the platinum-based anti-cancer therapies (oxaliplatin and cisplatin), vinca alkaloids (vincristine and vinblastine), taxanes (paclitaxel and docetaxel), proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). These classes have differing anti-neoplastic mechanisms and likely different mechanisms for neuropathy. Evidence suggests that a number of mechanisms are shared between classes of chemotherapeutics, and most studies investigate the taxanes and the platinums. Currently, these mechanisms can be broadly separated into mitochondrial dysfunction and oxidative stress, microtubule disruption, neuroinflammation and immunological processes, and ion channel dysregulation. Mitochondrial and oxidative stress Bioenergetic pathways, predominantly via the oxidation of glucose through the Krebs cycle within the mitochondria, are responsible for the generation of ATP. Chemotherapeutics commonly target nucleolar DNA and may also affect mitochondrial DNA. Indeed, targeting mitochondrial DNA as a principal therapy is an area of ongoing research 10 . Whereas nucleolar DNA has well-established repair mechanisms, mitochondria do not. Flatters and Bennett showed that paclitaxel treatment in rats led to swollen vacuolated mitochondria that followed the course of pain-like behaviours for almost 3 months 11 . Mitochondrial dysfunction within sensory neurones has also been demonstrated by other chemotherapeutics 12 – 15 . Krukowski et al . found that cisplatin-induced mechanical allodynia is associated with mitochondrial damage in DRG but that the loss of intra-epidermal nerve fibres (IENFs), seen in patients with CIPN, is related to bioenergetic deficits in peripheral nerves 16 . Gregg et al . found that post-mortem platinum concentrations in patients who received platinum chemotherapy were highest in DRGs and demonstrated a linear relationship between DRG levels and cumulative dose 17 , and levels were higher in patients with neuropathy. Animal data suggest a dose-dependent accumulation within the mitochondria of DRG neurones 18 . Recently, gene expression analysis further supported mitochondrial dysfunction in patients who develop CIPN. Kober et al . 19 found that breast cancer patients who develop neuropathy after paclitaxel demonstrate differential expression in a number of pathways implicated in mitochondrial dysfunction, including oxidative stress 20 . Additionally, genetic polymorphisms in anti-oxidant pathways have been associated with an increased incidence of CIPN 21 . Numerous animal studies indicate that chemotherapy worsens oxidative stress 22 , 23 . Furthermore, anti-oxidants prevent the development of mitochondrial dysfunction, IENF loss and pain-like behaviours in animal models 24 , 25 . The anti-oxidant alpha-lipoic acid reduces neuropathy in patients with diabetes and also animal models of CIPN 26 . Concurrent administration of alpha-lipoic acid reduces neuropathic symptoms secondary to bortezomib with less alteration to chemotherapy regimen secondary to adverse events 27 . However, despite the neuroprotective effects of anti-oxidants in vitro studies 28 , there is little clinical evidence for other nutraceutical anti-oxidants in the prevention of CIPN 29 . Recently, however, a phase I trial showed that calmangafodipir, a manganese superoxide dismutase mimic that aids reactive oxygen species (ROS) degradation, reduces acute and chronic CIPN after oxaliplatin in patients 30 without affecting response to chemotherapy and life expectancy. Metformin can also reduce neuropathic behaviours via a reduction in oxidative stress 13 , 31 , 32 . Metformin treatment in 40 patients receiving oxaliplatin reduced National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade 2 and 3 neuropathy with a moderate reduction in neurotoxicity score and a modest reduction in pain 33 . Mitochondria play a key role not only in ROS regulation but in numerous other cellular processes, including calcium buffering, apoptosis and energy production via oxidative phosphorylation. Duggett et al . have shown that whereas basal respiration and ATP turnover were unaffected in DRG mitochondria of paclitaxel treated rats, maximal respiration and spare reserve capacity were greatly reduced at peak pain behaviour 12 . This indicates a reduced ability of these neurones to respond to stress, and the authors postulated that a switch to glycolysis could be an adaptive mechanism to reduce harmful ROS production. Schwann cells play a crucial role in the regrowth of peripheral axons after injury; however, Nishida et al . found that accumulation of platinum compounds within Schwann cells was much lower than that in peripheral nerves and DRG 18 . Conversely, Imai et al . suggested that in vitro platinum compounds cause mitochondrial dysfunction in Schwann cells at drug concentrations lower than those required to induce neurotoxicity 34 , suggesting a greater role for mitochondrial dysfunction in Schwann cells in CIPN. In animal models, treatment with pifithrin-μ, a molecule that suppresses mitochondrial damage, improves mitochondrial morphology, bioenergetics and IENF density while reducing pain behaviours 14 , 35 . Combined with evidence that it may act synergistically with the anti-cancer mechanisms of chemotherapeutics 35 , 36 , pifithrin-μ represents an exciting prospect in cancer care. Glia and neuroinflammation Glia are key in maintaining homeostasis and immunity in the central nervous system in both health and disease. In models of non-chemotherapy-induced neuropathy, microglia have been found to play an integral role in the development of the pain state 37 , 38 . Oxaliplatin-treated rats displayed persistent mechanical allodynia, sensory deficits and decreased density of IENFs 39 . Hu et al . showed a persistent activation of spinal cord microglia through strengthening of triggering receptor expressed on myeloid cells 2 (TREM2) signalling and demonstrated that either inhibiting microglia with minocycline or interrupting TREM2 signalling improved pain-like behaviours and IENF density 40 . Furthermore, an agonist at the CB2 cannabinoid receptor, colocalised with spinal microglia, inhibited microgliosis and pain behaviours in an animal model of paclitaxel-induced neuropathy 41 . Despite these findings, astrogliosis rather than microgliosis is thought to be of greater importance to the development of CIPN 42 , 43 , while in some models, astrocyte inhibition with minocycline prevented the development of pain-like behaviours. But how would astrocyte activation lead to the development of CIPN? One proposed mechanism in a rat model of oxaliplatin-induced painful neuropathy is dysregulation of spinal adenosine kinase expression in astrocytes 44 . This may lead to activation of NRLP3/interleukin 1 beta (NRLP3/IL1β) pathway, promoting dorsal horn neuronal excitability with concurrent suppression of the anti-inflammatory IL-10 system, leading to central sensitisation and pain behaviours 44 , 45 . Importantly, restoration of adenosine signalling with an A3AR adenosine receptor agonist prevents the development of both astrocytosis and pain behaviours 45 . Another mechanism proposed in rodent models is through the alteration of sphingolipid signalling within astrocytes in the superficial layers of the dorsal horn of the spinal cord, an area concerned with nociceptive transmission 46 , 47 . Maladapted sphingolipid metabolism, through direct bortezomib effects and increased IL-1β, may increase glutamatergic transmission and consequently nociceptive transmission and pain behaviours 47 . Reasons for the discrepancies in the role glia play in CIPN remain unclear but the discrepancies may be due to variations in chemotherapy, species, time point and sex studied. Pain phenotype differs greatly between male and female patients, and the pathophysiology in animal models is also sex-dependent 48 . In animal models of bortezomib-induced peripheral neuropathy, modulation of sphingolipid signalling attenuates pain behaviours in male but not female rodents 47 . Additional examples of sexual dimorphism are found in paclitaxel-induced peripheral neuropathy, and Toll-like receptor 9 (TLR9) expression in macrophages infiltrating DRG plays a role in the development of pathophysiological changes and behaviours in male mice but not females 49 . Macrophage infiltration into DRG and peripheral nerves has been seen in a number of animal models of CIPN, and as with other models of neuropathic pain, activation of TLR4 seems to be crucial 50 – 52 . Clinically, minocycline treatment reduced only the acute pain syndrome associated with paclitaxel infusion but not the development of chronic CIPN 53 . Additionally, in another phase 2 trial, minocycline failed to prevent oxaliplatin-induced peripheral neuropathy 54 . Despite previous pre-clinical trials indicating minocycline’s efficacy at inhibiting astrocyte activation and pain behaviours, its actions have been ascribed predominantly to inhibition of microglia and not astrocytes 55 , 56 . Given the differential role that microglia may have in CIPN, minocycline’s lack of clinical efficacy may be of no surprise and neuroinflammation still represents a worthy area for continued research in the prevention of CIPN. Fingolimod, a drug used in the treatment of multiple sclerosis, downregulates the S1PR1 receptor found on astrocytes. Antagonism of this receptor has been shown to reverse immunochemical and behavioural changes in rodent models 47 . This presents the exciting prospect of a potentially new mechanistic target with a readily available therapeutic agent; however, additional trials are required to assess both its effects on CIPN and importantly tumour activity. Ion channels Pre-clinical studies have highlighted many chemotherapy-induced changes in ion channel expression, possibly driving behavioural changes in other neuropathic pain states 57 . Changes in sodium channel expression and their sensitisation increase spontaneous neuronal firing and decrease activation threshold 58 , mechanisms possibly analogous to the allodynia, hyperalgesia and paroxysmal sensations of CIPN. In patients, sodium channel dysfunction is found in acute oxaliplatin toxicity 59 , and sodium channel polymorphisms may have a causal role in the development of acute and possibly chronic CIPN 60 . Furthermore, Na v 1.7 channel has been found to be similarly upregulated in nociceptive neurones in both a rat model and patients with chronic paclitaxel-induced peripheral neuropathy 61 . Although dysregulation of other sodium channels is seen in pre-clinical studies of CIPN 62 , the clinical efficacy of sodium channel blockers has been disappointing 63 . Potassium channel dysregulation is present in animal models of CIPN 64 . Acutely, oxaliplatin leads to the down-regulation of potassium channels in animal models 62 , and Poupon et al . found that treatment with a riluzole (a potassium channel activator) prevents the development of persistent CIPN in mice 65 . A phase 2 randomised controlled trial (RCT) investigating the efficacy of riluzole in the prevention of CIPN is under way 66 . Transient receptor potential (TRP) channels are critical in temperature transduction. Oxaliplatin treatment leads to an increased expression of TRPA1, TRPV1 and TRPM8 in sensory neurones 67 . Interestingly, suppression of TREK-1 and TRAAK potassium channels (and an increase in pro-excitatory Na v 1.8 and HCN ion channels) is found on neurones expressing TRPM8, a receptor responsive to cold 62 . This may present a mechanism through which menthol provides symptomatic relief and oxaliplatin produces cold hypersensitivity acutely. Although calcium channel modulation has shown promise in animal models of CIPN 68 , 69 , no direct calcium channel blockers are in clinical use for neuropathic pain. Cisplatin causes an increase in the calcium channel alpha-2-delta subunit, the target of gabapentinoids 70 , and both topical and systemic treatment with gabapentinoids have been found to be beneficial in rat models of CIPN 71 , 72 . Despite this, treatment with pregabalin for 3 days before and after each cycle of oxaliplatin failed to prevent CIPN in patients 73 . Clinical features Risk factors There are many potential predictors in the development of CIPN, including patient-related factors, such as increased age, pre-existing neuropathy, smoking status, and impaired renal function, and chemotherapy-related factors, such as type of chemotherapy, cumulative chemotherapy dose, concurrent chemotherapy treatment, and duration of infusion 74 – 76 . Certain cancers may cause a subclinical neuropathy which may predispose patients to CIPN and worsen outcomes 77 . Genetic markers have been implicated in chemotherapy-related toxicity, and a number of genome-wide association studies have looked at polymorphisms associated with CIPN. A number of polymorphisms have been identified, none of which (at present) has sufficient prognostic value to be of use in the clinical context 78 . Argyriou et al . 78 called for improved methodology and more standardised diagnostic and severity grading to better inform future studies. Assessment of CIPN Despite challenges in prevention and treatment, assessment for CIPN should occur before, during and after chemotherapy. Assessment should include (1) diagnosis (including possible differential diagnoses), (2) severity (including functional impairment) and (3) time course of symptoms and relationship to chemotherapy. Diagnosis of CIPN requires a full history and examination ( Table 1 ). Within the history, it is important to determine pre-existing risk factors for neuropathy such as diabetes, vitamin deficiency, alcohol use and previous chemotherapy. Blood tests, including a full blood count, comprehensive metabolic profile, measurement of erythrocyte sedimentation rate, fasting blood glucose, vitamin B 12 , and thyroid-stimulating hormone levels, should be considered to help rule out other causative or contributory causes for neuropathy. Table 1. Key elements in history and examination. History Examination • Details of chemotherapy regimen • Number of cycles, dose and cumulative dose • Onset of symptoms in relation to chemotherapy • “Coasting” assessment (neuropathy occurring or worsening after chemotherapy cessation) • Evidence of change over time (better or worse) Symptoms • Distribution (hands, feet or more proximal) • Numbness, paraesthesia, pain, spontaneous or evoked • Motor or sympathetic dysfunction • Functionality and interference on activities Sensation • Light touch • Pinprick or painful stimulus • Vibration sense • Cold/hot sensation Other • Deep tendon reflexes • Motor power • Balance Painful CIPN is a subset that may benefit from further characterisation with multidimensional pain assessment tools. The McGill Pain Questionnaire (MPQ) and the Brief Pain Inventory (BPI) have been validated for use in cancer pain 79 and although they both assess sensory aspects, including severity, the BPI also assesses impact on function. Likewise, screening tools may aid in the assessment of neuropathic pain. Two such tools, the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and Douleur Neuropathique 4 (DN4) 80 , 81 , have good sensitivity and specificity in cancer pain but are not validated in CIPN. Furthermore, although chemotherapy is a common treatment for childhood cancers and the subsequent neuropathy may differ in phenotype from that of adults 82 , 83 , there are few validated tools for the assessment of CIPN in children. One such score is the paediatric-modified total neuropathy score (ped-mTNS), which has been validated in a small group of children undergoing vincristine or cisplatin chemotherapy for leukaemia 84 ; however, the 2008 Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (PedIMMPACT) called for the development of reliable and valid tools for use in children 85 . Numerous tools have been developed for the assessment of CIPN; however, there is notable inter-observer variation between these scales. Clinical rated scales such as the Ajani scale, World Health Organization, Eastern Cooperative Oncology Group neuropathy scale, and NCI-Common Toxicity Criteria (NCI-CTC) have limited assessment of pain 86 and may not truly reflect the incidence of adverse neuropathy, leading to inappropriate treatment reduction or cessation. Furthermore, clinician-rated neuropathy scales underestimate the severity of CIPN when compared with patient-reported measures 87 . In a recent systematic review, Haryani et al . suggested that, owing to their psychometric properties and practicality, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) and total neuropathy score (TNS) (see below) were the most appropriate assessment tools available 88 . Yet other studies are contradictory; this is in line with a recent DELPHI survey which showed there is little consensus amongst clinicians 89 . Fact/GOG-Ntx was developed for assessing the impact of neuropathy on quality of life after chemotherapy for gynaecological cancer and consists of questions on physical, social, emotional and functional wellbeing with an additional 11-question neurotoxicity subscale. This subscale has been used independently and demonstrates good sensitivity in diagnosis and responsiveness to treatment 90 and has been validated in other non-gynaecological, non-cisplatin/paclitaxel patients. Further shortening the neurotoxic subscale to four sensory questions maintains the validity and sensitivity while reducing the burden of patient questions 91 . The Patient Neurotoxicity Questionnaire (PNQ) evaluates sensory, motor and functional components of neuropathy with good sensitivity to change over time and showed improved reporting of CIPN when compared with clinician reporting tools such as the NCI-CTC (see above). Importantly, the PNQ assesses the impact of neuropathy on 22 activities (such as fastening buttons or typing) that are not assessed with other tools, thus representing a more holistic patient-centred assessment of neuropathy. The TNS is an eight-item score of patient report of neuropathic symptoms, examination findings to pinprick, vibration and deep tendon reflexes and nerve conduction studies (NCSs). A shortened version without the electrophysiological factors has been validated: the TNSc (clinical version of the TNS) 92 ; both have been shown to be more sensitive to CIPN changes than NCI-CTC and comparable in changes to quality-of-life measures 93 . Importantly, TNS delivers both clinician- and patient-rated components. Quality-of-life measures are commonly not assessed in many CIPN tools. The European Organization of Research and Treatment of Cancer (EORTC), 20-item quality-of-life questionnaire, is sensitive to changes in quality of life secondary to CIPN 94 . Investigations There has been a great deal of interest in phenotyping CIPN by using minimally invasive tools such as NCSs, quantitative sensory testing (QST) and IENF density. It seems sensible that underlying mechanisms may translate to differing patterns of neuronal loss and therefore differences in functional deficits, yet in practice this theory is not robust. Traditionally, CIPN has been characterised as a predominant sensory neuropathy effecting large myelinated fibre function, and nerve biopsies from patients with cisplatin- and paclitaxel-induced neuropathy show a loss of large fibres with axonal atrophy and secondary demyelination 95 , 96 . Platinum chemotherapeutics cause neuronal cycle arrest within the DRG and therefore likely cause a neuronopathy (also referred to as ganglionopathy) and anterograde neuronal degeneration. On NCS, this would manifest as non-length-dependent neuropathy affecting both the proximal and distal neurone. In contrast, chemotherapeutics interfering with mitochondrial or microtubule function impair axonal transportation giving a length-dependent axonal polyneuropathy, leading to a die back of intraepidermal nerve fibres. However, owing to poor correlation with clinical symptoms, NCSs cannot be routinely recommended. Furthermore, NCSs assess predominantly large-fibre function, missing small-fibre changes that may occur with painful CIPN. Owing to its ability to assess large- and small-fibre types, QST may be of use in the phenotyping of neuropathic pain 97 and therefore has been proposed as a useful tool in CIPN 98 . In patients with paclitaxel-induced peripheral neuropathy, the reduction in light touch and vibration detection thresholds seen in hands and feet supports the mechanism of paclitaxel causing a distal neuropathy predominantly effecting the large, non-nociceptive neurones 99 . Additionally, some report that thermal detection thresholds and pinprick detection are minimally affected, indicating that small-fibre function is preserved in this group. This is in contrast to findings in patients with vincristine and bortezomib-induced neuropathy, with some studies reporting changes in pinprick perception and warm detection thresholds suggesting small, nociceptive fibre dysfunction in this group of patients 100 , 101 . Pre-existing QST sensory deficits increase the risk of developing CIPN 102 ; in some cases, cancer itself may be responsible for QST changes 103 . Although the QST sensory profile may differ between agents 104 , 105 , QST profiles for painful and painless CIPN may be similar 106 and changes in QST may occur later than symptoms develop 107 . Furthermore, QST requires expertise and time and consequently is not commonly used in routine clinical practice for the evaluation of CIPN. Skin punch biopsy can inform the diagnosis of small-fibre neuropathies. In CIPN, similar to other small-fibre neuropathies, IENF loss is observed 108 . Taking comparative distal thigh and distal leg punch biopsies can help differentiate between a length-dependent neuropathy or a neuronopathy; however, evaluating CIPN using IENF densities has been found to be unreliable; there is a large overlap between different chemotherapeutics, and results conflict with other assessment tools 109 – 111 . Furthermore, although punch biopsy can be repeated, it is time-consuming and invasive and IENF density has been found to be a poor correlate of pain 112 . Other techniques for assessing neuropathy have yet to be fully validated. Nevertheless, simple bedside measures such as vibration sense, light touch and pinprick have good validity in the measurement of neuropathy 113 . Prevention Reducing regional perfusion (cryotherapy) may reduce CIPN; cooling gloves and stockings have been shown to reduce the risk of desquamation and nail changes associated with chemotherapy. Of the three published trials, only one showed benefit 114 . Owing to poorly tolerated treatment or a greater-than-expected control group response, the other studies were negative 115 – 117 . In 2014, the American Society of Clinical Oncology evaluated 42 studies while developing guidelines on the prevention of CIPN 63 . Owing to a lack of high-quality data, they were unable to make any recommendations and encouraged additional research. Treatment Pharmacological RCT evidence of treatments in CIPN suggested that duloxetine is the only anti-neuropathic agent with evidence of benefit 118 . Many CIPN RCTs fail to meet the IMMPACT guidelines for outcome measures in clinical trials 119 , 120 . Nevertheless, a recent comparative study showed that venlafaxine and duloxetine reduced pain in established CIPN 121 . Careful phenotyping may help, as demonstrated with the improved efficacy of oxcarbazepine in the “irritable nociceptor” subgroup 122 . Phenotyping patients for biological and psychosocial characteristics may give additional insight 122 – 125 . Topical treatments are an attractive option for the management of CIPN. A small non-randomised study of topical menthol in 52 patients showed improved BPI scores 126 , and combination therapy with baclofen, amitriptyline and ketamine showed an improvement on some of the EORTC QLQ-CIPN-20 measures 127 . Topical 8% capsaicin patch application following CIPN has been shown to improve continuous pain, neuropathic pain symptoms, and patient global impression of change 128 . This treatment has also been found to improve IENF density, suggesting underlying disease modification 128 . There is increasing enthusiasm for the use of cannabinoids in the treatment of many chronic pain states. Agonism at CB1 and CB2 receptors has shown analgesia in rodent models of CIPN 129 – 133 but these findings have not translated into evidence of clinical efficacy. One published pilot study of nabiximols (THC:CBD mix) in 15 patients with CIPN 134 showed no significant improvement in pain, but a 2-point decrease over placebo was seen in five patients classified as “responders” 134 . Without specific evidence for CIPN, clinicians extrapolate treatments from other neuropathic pain states 135 . Interestingly, strong opioids have some of the best “numbers needed to treat” (NNTs) for neuropathic pain (NNT 4.3, 95% confidence interval 3.4–5.8) 135 . Some clinicians may advocate the use of opioids in CIPN, however with increasing survivorship amongst patients with cancer, the possible benefits of opioids should be continually weighed up against the risk of long-term opioid therapy 2 . Non-pharmacological Neuromodulation has shown promise in various neuropathic pain states 136 . A number of case reports indicate that neuromodulation may help refractory CIPN 137 , 138 , but RCT data are lacking. A recent study found that the use of wireless transcutaneous electrical nerve stimulation significantly improved some measures of CIPN, including pain, numbness and tingling 139 . Furthermore, scrambler therapy (a novel transcutaneous neurostimulation technique) has been postulated as a potential treatment 140 but was no more effective than sham therapy in a recent RCT 141 . Acupuncture A Cochrane Review of the efficacy of acupuncture in the treatment of cancer pain showed insufficient evidence of its efficacy 142 . Since then, a number of trials of acupuncture in CIPN have demonstrated improvements in several domains 143 – 145 . A systematic review concluded that there was insufficient evidence to recommend acupuncture for the treatment of CIPN 146 , although low risk of harm and possible benefit may allow its pragmatic use in painful CIPN. Physical therapy Exercise has been shown to improve a number of facets that contribute to morbidity associated with CIPN, including balance and strength 147 , 148 , numbness, tingling, and hot and cold sensations 149 . One study found that, on analysis of the quality-of-life data, exercise had a moderate effect on pain in patients undergoing chemotherapy; however, this was not limited to CIPN 150 . Psychological therapy Psychological factors have been shown to play a role in both the initiation and maintenance of a number of chronic pain states 151 . The activity of duloxetine, via enhancing descending inhibitory pathways, suggests that alteration of mood may play a role. In favour of this viewpoint, a study of 111 patients who received treatment for breast cancer found that pre-existing anxiety and pre-therapy numbness were the only factors to predict CIPN eight months later 152 . Knoerl et al . found that an eight-week web-based cognitive behavioural programme led to modest improvements in worst pain with no differences in mean pain 153 . It was hypothesised that this would be due to improvements in fatigue, anxiety, sleep-related factors, or depression; however, a follow-up analysis was unable to substantiate these findings 154 . Future directions Pre-clinical studies have shown that antagonism of the sigma 1 receptor (present on mitochondrial endoplasmic reticulum) is able to reduce mitochondrial structural changes and pain behaviours that occur in CIPN. A phase II clinical trial found that sigma 1 antagonist treatment during FOLFOX chemotherapy diminished cold hypersensitivity, reduced the dropout rate and allowed a higher cumulative dose of oxaliplatin 155 . Although the long-term pain outcomes are not known, this highlights a pathway for potential therapeutics that could improve CIPN. Summary Despite an ever-expanding body of literature behind the pathophysiology and treatment of CIPN, new treatment options are still limited, and a proportion of patients continue to have difficulty controlling symptoms causing a significant impact on quality of life. Guided by the pre-clinical literature, novel targets that may help prevent CIPN are beginning to emerge. However, with continual advancements in chemotherapeutic agents with novel mechanisms, it is important that ongoing development of treatments for CIPN continue. F1000 recommended References 1. Arnold M, Rutherford MJ, Bardot A, et al. : Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019; 20 (11): 1493–505. PubMed Abstract | Publisher Full Text | Free Full Text 2. Brown M, Farquhar-Smith P: Pain in cancer survivors; filling in the gaps. Br J Anaesth. 2017; 119 (4): 723–36. PubMed Abstract | Publisher Full Text 3. Mols F, Beijers T, Vreugdenhil G, et al. : Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014; 22 (8): 2261–9. PubMed Abstract | Publisher Full Text 4. Seretny M, Currie GL, Sena ES, et al. : Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155 (12): 2461–70. PubMed Abstract | Publisher Full Text 5. Gutiérrez-Gutiérrez G, Sereno M, Miralles A, et al. : Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010; 12 (2): 81–91. PubMed Abstract | Publisher Full Text 6. Bhatnagar B, Gilmore S, Goloubeva O, et al. : Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. SpringerPlus. 2014; 3 : 366. PubMed Abstract | Publisher Full Text | Free Full Text 7. Currie GL, Angel-Scott HN, Colvin L, et al. : Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis. PLoS Biol. 2019; 17 (5): e3000243. PubMed Abstract | Publisher Full Text | Free Full Text 8. Griffiths LA, Duggett NA, Pitcher AL, et al. : Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. Pain Res Manag. 2018; 2018 : 8217613. PubMed Abstract | Publisher Full Text | Free Full Text 9. Hama A, Natsume T, Ogawa S, et al. : Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain. Pain Res Manag. 2018; 2018 : 1630709. PubMed Abstract | Publisher Full Text | Free Full Text 10. Wisnovsky SP, Wilson JJ, Radford RJ, et al. : Targeting mitochondrial DNA with a platinum-based anticancer agent. Chem Biol. 2013; 20 (11): 1323–8. PubMed Abstract | Publisher Full Text | Free Full Text 11. Flatters SJL, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006; 122 (3): 245–57. PubMed Abstract | Publisher Full Text | Free Full Text 12. Duggett NA, Griffiths LA, Flatters SJL: Paclitaxel-induced painful neuropathy is associated with changes in mitochondrial bioenergetics, glycolysis, and an energy deficit in dorsal root ganglia neurons. Pain. 2017; 158 (8): 1499–508. PubMed Abstract | Publisher Full Text | Free Full Text 13. Ludman T, Melemedjian OK: Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy. Mol Pain. 2019; 15 : 174480691985004. PubMed Abstract | Publisher Full Text | Free Full Text 14. Maj MA, Ma J, Krukowski KN, et al. : Inhibition of Mitochondrial p53 Accumulation by PFT-μ Prevents Cisplatin-Induced Peripheral Neuropathy. Front Mol Neurosci. 2017; 10 : 108. PubMed Abstract | Publisher Full Text | Free Full Text 15. Xiao WH, Zheng H, Zheng FY, et al. : Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience. 2011; 199 : 461–9. PubMed Abstract | Publisher Full Text | Free Full Text 16. Krukowski K, Ma J, Golonzhka O, et al. : HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017; 158 (6): 1126–37. PubMed Abstract | Publisher Full Text | Free Full Text 17. Gregg RW, Molepo JM, Monpetit VJ, et al. : Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992; 10 (5): 795–803. PubMed Abstract | Publisher Full Text 18. Nishida K, Takeuchi K, Hosoda A, et al. : Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. Life Sci. 2018; 207 : 516–24. PubMed Abstract | Publisher Full Text 19. Kober KM, Olshen A, Conley YP, et al. : Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Mol Pain. 2018; 14 : 174480691881646. PubMed Abstract | Publisher Full Text | Free Full Text 20. Ziegler D, Hanefeld M, Ruhnau KJ, et al. : Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995; 38 (12): 1425–33. PubMed Abstract | Publisher Full Text 21. Katayanagi S, Katsumata K, Mori Y, et al. : GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy. Oncol Lett. 2019; 17 (3): 2897–2904. PubMed Abstract | Publisher Full Text | Free Full Text 22. Ma J, Kavelaars A, Dougherty PM, et al. : Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer. 2018; 124 (11): 2289–98. PubMed Abstract | Publisher Full Text | Free Full Text 23. Shim HS, Bae C, Wang J, et al. : Peripheral and central oxidative stress in chemotherapy-induced neuropathic pain. Mol Pain. 2019; 15 : 1744806919840098. PubMed Abstract | Publisher Full Text | Free Full Text 24. Janes K, Doyle T, Bryant L, et al. : Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain. 2013; 154 (11): 2432–40. PubMed Abstract | Publisher Full Text | Free Full Text 25. Jin HW, Flatters SJ, Xiao WH, et al. : Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol. 2008; 210 (1): 229–37. PubMed Abstract | Publisher Full Text | Free Full Text 26. Papanas N, Ziegler D: Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014; 15 (18): 2721–31. PubMed Abstract | Publisher Full Text 27. Maschio M, Zarabla A, Maialetti A, et al. : Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. Integr Cancer Ther. 2018; 17 (4): 1115–24. PubMed Abstract | Publisher Full Text | Free Full Text 28. Popović J, Klajn A, Paunesku T, et al. : Neuroprotective Role of Selected Antioxidant Agents in Preventing Cisplatin-Induced Damage of Human Neurons In Vitro . Cell Mol Neurobiol. 2019; 39 (5): 619–36. PubMed Abstract | Publisher Full Text | Free Full Text 29. Schloss JM, Colosimo M, Airey C, et al. : Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr. 2013; 32 (6): 888–93. PubMed Abstract | Publisher Full Text 30. Glimelius B, Manojlovic N, Pfeiffer P, et al. : Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ®) : a placebo-controlled randomised phase II study (PLIANT). Acta Oncol. 2018; 57 (3): 393–402. PubMed Abstract | Publisher Full Text 31. Chakraborty A, Chowdhury S, Bhattacharyya M: Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011; 93 (1): 56–62. PubMed Abstract | Publisher Full Text 32. Hou X, Song J, Li XN, et al. : Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun. 2010; 396 (2): 199–205. PubMed Abstract | Publisher Full Text 33. El-Fatatry BM, Ibrahim OM, Hussien FZ, et al. : Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. Int J Colorectal Dis. 2018; 33 (12): 1675–83. PubMed Abstract | Publisher Full Text 34. Imai S, Koyanagi M, Azimi Z, et al. : Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Sci Rep. 2017; 7 (1): 5947. PubMed Abstract | Publisher Full Text | Free Full Text 35. Krukowski K, Nijboer CH, Huo X, et al. : Prevention of chemotherapy-induced peripheral neuropathy by the small-molecule inhibitor pifithrin-μ. Pain. 2015; 156 (11): 2184–92. PubMed Abstract | Publisher Full Text | Free Full Text 36. McKeon A, Egan A, Chandanshive J, et al. : Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin-μ. In Vitro Synergy Quantification of Pifithrin-μ Combined with Pt Drugs in Prostate and Colorectal Cancer Cells. Molecules. 2016; 21 (7): pii: E949. PubMed Abstract | Publisher Full Text | Free Full Text 37. Zhao H, Alam A, Chen Q, et al. : The role of microglia in the pathobiology of neuropathic pain development: what do we know? Br J Anaesth. 2017; 118 (4): 504–16. PubMed Abstract | Publisher Full Text 38. Sayo A, Konishi H, Kobayashi M, et al. : GPR34 in spinal microglia exacerbates neuropathic pain in mice. J Neuroinflammation. 2019; 16 (1): 82. PubMed Abstract | Publisher Full Text | Free Full Text 39. Di Cesare Mannelli L, Pacini A, Micheli L, et al. : Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol. 2014; 261 : 22–33. PubMed Abstract | Publisher Full Text 40. Hu LY, Zhou Y, Cui WQ, et al. : Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice. Brain Behav Immun. 2018; 68 : 132–45. PubMed Abstract | Publisher Full Text 41. Wu J, Hocevar M, Bie B, et al. : Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. J Pain. 2019; 20 (5): 501–14. PubMed Abstract | Publisher Full Text 42. Zhang H, Yoon SY, Zhang H, et al. : Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. J Pain. 2012; 13 (3): 293–303. PubMed Abstract | Publisher Full Text | Free Full Text 43. Robinson CR, Zhang H, Dougherty PM: Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. Neuroscience. 2014; 274 : 308–17. PubMed Abstract | Publisher Full Text | Free Full Text 44. Janes K, Wahlman C, Little JW, et al. : Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. Brain Behav Immun. 2015; 44 : 91–9. PubMed Abstract | Publisher Full Text | Free Full Text 45. Wahlman C, Doyle TM, Little JW, et al. : Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. Pain. 2018; 159 (6): 1025–34. PubMed Abstract | Publisher Full Text | Free Full Text 46. Janes K, Little JW, Li C, et al. : The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1. J Biol Chem. 2014; 289 (30): 21082–97. PubMed Abstract | Publisher Full Text | Free Full Text 47. Stockstill K, Doyle TM, Yan X, et al. : Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med. 2018; 215 (5): 1301–13. PubMed Abstract | Publisher Full Text | Free Full Text 48. Mapplebeck JCS, Dalgarno R, Tu Y, et al. : Microglial P2X4R-evoked pain hypersensitivity is sexually dimorphic in rats. Pain. 2018; 159 (9): 1752–1763. PubMed Abstract 49. Luo X, Huh Y, Bang S, et al. : Macrophage Toll-like Receptor 9 Contributes to Chemotherapy-Induced Neuropathic Pain in Male Mice. J Neurosci. 2019; 39 (35): 6848–64. PubMed Abstract | Publisher Full Text | Free Full Text 50. Zhang H, Li Y, de Carvalho-Barbosa M, et al. : Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J Pain. 2016; 17 (7): 775–86. PubMed Abstract | Publisher Full Text | Free Full Text 51. Li Y, Zhang H, Zhang H, et al. : Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy. J Pain. 2014; 15 (7): 712–25. PubMed Abstract | Publisher Full Text | Free Full Text 52. Liu CC, Lu N, Cui Y, et al. : Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain. 2010; 6 : 76. PubMed Abstract | Publisher Full Text | Free Full Text 53. Pachman DR, Dockter T, Zekan PJ, et al. : A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017; 25 (11): 3407–16. PubMed Abstract | Publisher Full Text 54. Wang XS, Shi Q, Bhadkamkar NA, et al. : Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019; 58 (4): 662–71. PubMed Abstract | Publisher Full Text | Free Full Text 55. Tikka T, Fiebich BL, Goldsteins G, et al. : Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci. 2001; 21 (8): 2580–8. PubMed Abstract | Publisher Full Text | Free Full Text 56. Yrjänheikki J, Tikka T, Keinänen R, et al. : A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A. 1999; 96 (23): 13496–500. PubMed Abstract | Publisher Full Text | Free Full Text 57. Aromolaran KA, Goldstein PA: Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect? Mol Pain. 2017; 13 : 174480691771469. PubMed Abstract | Publisher Full Text | Free Full Text 58. Bennett DL, Clark AJ, Huang J, et al. : The Role of Voltage-Gated Sodium Channels in Pain Signaling. Physiol Rev. 2019; 99 (2): 1079–151. PubMed Abstract | Publisher Full Text 59. Heide R, Bostock H, Ventzel L, et al. : Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation. Clin Neurophysiol. 2018; 129 (3): 694–706. PubMed Abstract | Publisher Full Text 60. Argyriou AA, Cavaletti G, Antonacopoulou A, et al. : Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013; 119 (9): 3570–7. PubMed Abstract | Publisher Full Text 61. Li Y, North RY, Rhines LD, et al. : DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain. J Neurosci. 2018; 38 (5): 1124–36. PubMed Abstract | Publisher Full Text | Free Full Text 62. Descoeur J, Pereira V, Pizzoccaro A, et al. : Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011; 3 (5): 266–78. PubMed Abstract | Publisher Full Text | Free Full Text 63. Hershman DL, Lacchetti C, Dworkin RH, et al. : Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32 (18): 1941–67. PubMed Abstract | Publisher Full Text 64. Viatchenko-Karpinski V, Ling J, Gu JG: Down-regulation of Kv4.3 channels and a-type K + currents in V2 trigeminal ganglion neurons of rats following oxaliplatin treatment. Mol Pain. 2018; 14 (14): 1744806917750995. PubMed Abstract | Publisher Full Text | Free Full Text 65. Poupon L, Lamoine S, Pereira V, et al. : Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology. 2018; 140 : 43–61. PubMed Abstract | Publisher Full Text 66. Kerckhove N, Busserolles J, Stanbury T, et al. : Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. BMJ Open. 2019; 9 (6): e027770. PubMed Abstract | Publisher Full Text | Free Full Text 67. Chukyo A, Chiba T, Kambe T, et al. : Oxaliplatin-induced changes in expression of transient receptor potential channels in the dorsal root ganglion as a neuropathic mechanism for cold hypersensitivity. Neuropeptides. 2018; 67 : 95–101. PubMed Abstract | Publisher Full Text 68. Rigo FK, Dalmolin GD, Trevisan G, et al. : Effect of ω-conotoxin MVIIA and Phα1β on paclitaxel-induced acute and chronic pain. Pharmacol Biochem Behav. 2013; 114–115 : 16–22. PubMed Abstract | Publisher Full Text 69. Flatters SJ, Bennett GJ: Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004; 109 (1–2): 150–61. PubMed Abstract | Publisher Full Text 70. Dolphin AC: Calcium channel auxiliary α 2 δ and β subunits: trafficking and one step beyond. Nat Rev Neurosci. 2012; 13 (8): 542–55. PubMed Abstract | Publisher Full Text 71. Han FY, Kuo A, Nicholson JR, et al. : Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatin-induced peripheral neuropathy. Clin Exp Pharmacol Physiol. 2018; 45 (10): 1067–75. PubMed Abstract | Publisher Full Text 72. Shahid M, Subhan F, Ahmad N, et al. : Efficacy of a topical gabapentin gel in a cisplatin paradigm of chemotherapy-induced peripheral neuropathy. BMC Pharmacol Toxicol. 2019; 20 (1): 51. PubMed Abstract | Publisher Full Text | Free Full Text 73. de Andrade DC, Jacobsen Teixeira M, Galhardoni R, et al. : Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist. 2017; 22 (10): 1154–e105. PubMed Abstract | Publisher Full Text | Free Full Text 74. Hershman DL, Till C, Wright JD, et al. : Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016; 34 (25): 3014–22. PubMed Abstract | Publisher Full Text | Free Full Text 75. Uwah AN, Ackler J, Leighton JC Jr, et al. : The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer. 2012; 11 (4): 275–9. PubMed Abstract | Publisher Full Text 76. Vincenzi B, Frezza AM, Schiavon G, et al. : Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013; 21 (5): 1313–9. PubMed Abstract | Publisher Full Text 77. Argyriou AA, Iconomou G, Kalofonos HP: Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008; 112 (5): 1593–9. PubMed Abstract | Publisher Full Text 78. Argyriou AA, Bruna J, Genazzani AA, et al. : Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017; 13 (8): 492–504. PubMed Abstract | Publisher Full Text 79. Caraceni A, Cherny N, Fainsinger R, et al. : Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002; 23 (3): 239–55. PubMed Abstract | Publisher Full Text 80. Bennett M: The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001; 92 (1–2): 147–57. PubMed Abstract | Publisher Full Text 81. Bouhassira D, Attal N, Alchaar H, et al. : Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005; 114 (1–2): 29–36. PubMed Abstract | Publisher Full Text 82. Sandier SG, Tobin W, Henderson ES: Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969; 19 (4): 367. PubMed Abstract | Publisher Full Text 83. Kandula T, Park SB, Cohn RJ, et al. : Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. Cancer Treat Rev. 2016; 50 : 118–28. PubMed Abstract | Publisher Full Text 84. Lavoie Smith EM, Li L, Hutchinson RJ, et al. : Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013; 36 (5): E49–E60. PubMed Abstract | Publisher Full Text | Free Full Text 85. McGrath PJ, Walco GA, Turk DC, et al. : Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain. 2008; 9 (9): 771–83. PubMed Abstract | Publisher Full Text 86. Postma TJ, Heimans JJ, Muller MJ, et al. : Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998; 9 (7): 739–44. PubMed Abstract | Publisher Full Text 87. Shimozuma K, Ohashi Y, Takeuchi A, et al. : Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17 (12): 1483–91. PubMed Abstract | Publisher Full Text 88. Haryani H, Fetzer SJ, Wu CL, et al. : Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review. Oncol Nurs Forum. 2017; 44 (3): E111–E123. PubMed Abstract | Publisher Full Text 89. McCrary JM, Goldstein D, Boyle F, et al. : Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer. 2017; 25 (11): 3485–93. PubMed Abstract | Publisher Full Text 90. Calhoun EA, Welshman EE, Chang CH, et al. : Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003; 13 (6): 741–8. PubMed Abstract 91. Huang HQ, Brady MF, Cella D, et al. : Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. Int J Gynecol Cancer. 2007; 17 (2): 387–93. PubMed Abstract | Publisher Full Text 92. Cavaletti G, Frigeni B, Lanzani F, et al. : The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007; 12 (3): 210–5. PubMed Abstract | Publisher Full Text 93. Cavaletti G, Cornblath DR, Merkies IS, et al. : The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013; 24 (2): 454–62. PubMed Abstract | Publisher Full Text | Free Full Text 94. Postma TJ, Aaronson NK, Heimans JJ, et al. : The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer. 2005; 41 (8): 1135–9. PubMed Abstract | Publisher Full Text 95. Thompson SW, Davis LE, Kornfeld M, et al. : Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984; 54 (7): 1269–75. PubMed Abstract | <a target="xrefwindow" id="d3628e3540" href="https://doi.org/10.1002/1097-0142(19841001)54:7 Publisher Full Text 96. Rowinsky EK, Chaudhry V, Cornblath DR, et al. : Neurotoxicity of Taxol. J Natl Cancer Inst Monogr. 1993; (15): 107–15. PubMed Abstract 97. Maier C, Baron R, Tölle TR, et al. : Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010; 150 (3): 439–50. PubMed Abstract | Publisher Full Text 98. Zhi WI, Chen P, Kwon A, et al. : Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing. Breast Cancer Res Treat. 2019; 178 (3): 587–95. PubMed Abstract | Publisher Full Text | Free Full Text 99. Dougherty PM, Cata JP, Cordella JV, et al. : Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004; 109 (1–2): 132–42. PubMed Abstract | Publisher Full Text 100. Cata JP, Weng HR, Burton AW, et al. : Quantitative sensory findings in patients with bortezomib-induced pain. J Pain. 2007; 8 (4): 296–306. PubMed Abstract | Publisher Full Text 101. Dougherty PM, Cata JP, Burton AW, et al. : Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage. 2007; 33 (2): 166–79. PubMed Abstract | Publisher Full Text 102. Wang XS, Shi Q, Dougherty PM, et al. : Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90 (3): 127–35. PubMed Abstract | Publisher Full Text | Free Full Text 103. Roldan CJ, Johnson C, Lee SO, et al. : Subclinical Peripheral Neuropathy in Patients with Head and Neck Cancer: A Quantitative Sensory Testing (QST) Study. Pain Physician. 2018; 21 (4): E419–E427. PubMed Abstract | Publisher Full Text | Free Full Text 104. Ventzel L, Madsen CS, Karlsson P, et al. : Chronic Pain and Neuropathy Following Adjuvant Chemotherapy. Pain Med. 2018; 19 (9): 1813–24. PubMed Abstract | Publisher Full Text 105. Forstenpointner J, Oberlojer VC, Naleschinski D, et al. : A-Fibers Mediate Cold Hyperalgesia in Patients with Oxaliplatin-Induced Neuropathy. Pain Pract. 2018; 18 (6): 758–67. PubMed Abstract | Publisher Full Text 106. Geber C, Breimhorst M, Burbach B, et al. : Pain in chemotherapy-induced neuropathy–more than neuropathic? Pain. 2013; 154 (12): 2877–87. PubMed Abstract | Publisher Full Text 107. Delmotte JB, Beaussier H, Auzeil N, et al. : Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study. Cancer Treat Res Commun. 2018; 17 : 31–6. PubMed Abstract | Publisher Full Text 108. Mangus LM, Rao DB, Ebenezer GJ: Intraepidermal Nerve Fiber Analysis in Human Patients and Animal Models of Peripheral Neuropathy: A Comparative Review. Toxicol Pathol. 2020; 48 (1): 59–70. PubMed Abstract | Publisher Full Text 109. Krøigård T, Svendsen TK, Wirenfeldt M, et al. : Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy-induced polyneuropathy symptoms and signs. Eur J Neurol. 2020; 27 (1): 68–76. PubMed Abstract | Publisher Full Text 110. Burakgazi AZ, Messersmith W, Vaidya D, et al. : Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011; 77 (10): 980–6. PubMed Abstract | Publisher Full Text | Free Full Text 111. Richardson PG, Xie W, Mitsiades C, et al. : Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27 (21): 3518–25. PubMed Abstract | Publisher Full Text | Free Full Text 112. Koskinen MJ, Kautio AL, Haanpää ML, et al. : Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Res. 2011; 31 (12): 4413–6. PubMed Abstract 113. Griffith KA, Dorsey SG, Renn CL, et al. : Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. J Peripher Nerv Syst. 2014; 19 (2): 127–35. PubMed Abstract | Publisher Full Text | Free Full Text 114. Hanai A, Ishiguro H, Sozu T, et al. : Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. J Natl Cancer Inst. 2018; 110 (2): 141–8. PubMed Abstract | Publisher Full Text | Free Full Text 115. Griffiths C, Kwon N, Beaumont JL, et al. : Cold therapy to prevent paclitaxel-induced peripheral neuropathy. Support Care Cancer. 2018; 26 (10): 3461–9. PubMed Abstract | Publisher Full Text 116. Ruddy KJ, Le-Rademacher J, Lacouture ME, et al. : Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. Breast. 2019; 48 : 89–97. PubMed Abstract | Publisher Full Text 117. Sundar R, Bandla A, Tan SS, et al. : Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Front Oncol. 2017; 6 : 274. PubMed Abstract | Publisher Full Text | Free Full Text 118. Smith EM, Pang H, Cirrincione C, et al. : Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309 (13): 1359. PubMed Abstract | Publisher Full Text | Free Full Text 119. Gewandter JS, Dworkin RH, Finnerup NB, et al. : Painful chemotherapy-induced peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology? Pain. 2017; 158 (1): 30–3. PubMed Abstract | Publisher Full Text | Free Full Text 120. Dworkin RH, Turk DC, Farrar JT, et al. : Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005; 113 (1–2): 9–19. PubMed Abstract | Publisher Full Text 121. Farshchian N, Alavi A, Heydarheydari S, et al. : Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol. 2018; 82 (5): 787–93. PubMed Abstract | Publisher Full Text 122. Demant DT, Lund K, Vollert J, et al. : The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014; 155 (11): 2263–73. PubMed Abstract | Publisher Full Text 123. Attal N, Rouaud J, Brasseur L, et al. : Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004; 62 (2): 218–25. PubMed Abstract | Publisher Full Text 124. Finnerup NB, Sindrup SH, Bach FW, et al. : Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002; 96 (3): 375–83. PubMed Abstract | Publisher Full Text 125. Mainka T, Malewicz NM, Baron R, et al. : Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. Eur J Pain. 2016; 20 (1): 116–29. PubMed Abstract | Publisher Full Text 126. Fallon MT, Storey DJ, Krishan A, et al. : Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support Care Cancer. 2015; 23 (9): 2769–77. PubMed Abstract | Publisher Full Text | Free Full Text 127. Barton DL, Wos EJ, Qin R, et al. : A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011; 19 (6): 833–41. PubMed Abstract | Publisher Full Text | Free Full Text 128. Anand P, Elsafa E, Privitera R, et al. : Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 2019; 12 : 2039–52. PubMed Abstract | Publisher Full Text | Free Full Text 129. Mulpuri Y, Marty VN, Munier JJ, et al. : Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. Neuropharmacology. 2018; 139 : 85–97. PubMed Abstract | Publisher Full Text | Free Full Text 130. Brenneman DE, Kinney WA, Ward SJ: Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity. J Mol Neurosci. 2019; 68 (4): 603–19. PubMed Abstract | Publisher Full Text | Free Full Text 131. Sierra S, Gupta A, Gomes I, et al. : Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain. ACS Pharmacol Transl Sci. 2019; 2 (4): 219–29. PubMed Abstract | Publisher Full Text | Free Full Text 132. King KM, Myers AM, Soroka-Monzo AJ, et al. : Single and combined effects of Δ 9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol. 2017; 174 (17): 2832–41. PubMed Abstract | Publisher Full Text | Free Full Text 133. Blanton HL, Brelsfoard J, DeTurk N, et al. : Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain. Drugs. 2019; 79 (9): 969–95. PubMed Abstract | Publisher Full Text 134. Lynch ME, Cesar-Rittenberg P, Hohmann AG: A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014; 47 (1): 166–73. PubMed Abstract | Publisher Full Text 135. Finnerup NB, Attal N, Haroutounian S, et al. : Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14 (2): 162–73. PubMed Abstract | Publisher Full Text | Free Full Text 136. Hofmeister M, Memedovich A, Brown S, et al. : Effectiveness of Neurostimulation Technologies for the Management of Chronic Pain: A Systematic Review. Neuromodulation. 2020; 23 (2): 150–157. PubMed Abstract | Publisher Full Text 137. Groenen PS, van Helmond N, Chapman KB: Chemotherapy-Induced Peripheral Neuropathy Treated with Dorsal Root Ganglion Stimulation. Pain Med. 2019; 20 (4): 857–9. PubMed Abstract | Publisher Full Text 138. Abd-Elsayed A, Schiavoni N, Sachdeva H: Efficacy of spinal cord stimulators in treating peripheral neuropathy: a case series. J Clin Anesth. 2016; 28 : 74–7. PubMed Abstract | Publisher Full Text 139. Gewandter JS, Chaudari J, Ibegbu C, et al. : Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support Care Cancer. 2019; 27 (5): 1765–74. PubMed Abstract | Publisher Full Text | Free Full Text 140. Loprinzi C, Le-Rademacher JG, Majithia N, et al. : Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020; 28 (3): 1183–97. PubMed Abstract | Publisher Full Text 141. Smith TJ, Razzak AR, Blackford AL, et al. : A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). J Palliat Care. 2020; 35 (1): 53–8. PubMed Abstract | Publisher Full Text 142. Paley CA, Johnson MI, Tashani OA, et al. : Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015; (10): CD007753. PubMed Abstract | Publisher Full Text | Free Full Text 143. Jeong YJ, Kwak MA, Seo JC, et al. : Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Trial. Evid Based Complement Alternat Med. 2018; 2018 : 1–11. PubMed Abstract | Publisher Full Text | Free Full Text 144. Zhi WI, Ingram E, Li SQ, et al. : Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain. Integr Cancer Ther. 2018; 17 (4): 1079–86. PubMed Abstract | Publisher Full Text | Free Full Text 145. Molassiotis A, Suen LKP, Cheng HL, et al. : A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy. Integr Cancer Ther. 2019; 18 : 1534735419836501. PubMed Abstract | Publisher Full Text | Free Full Text 146. Li K, Giustini D, Seely D: A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy. Curr Oncol. 2019; 26 (2): e147–e154. PubMed Abstract | Publisher Full Text | Free Full Text 147. Zimmer P, Trebing S, Timmers-Trebing U, et al. : Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2018; 26 (2): 615–24. PubMed Abstract | Publisher Full Text 148. Duregon F, Vendramin B, Bullo V, et al. : Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: A systematic review. Crit Rev Oncol Hematol. 2018; 121 : 90–100. PubMed Abstract | Publisher Full Text 149. Kleckner IR, Kamen C, Gewandter JS, et al. : Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018; 26 (4): 1019–28. PubMed Abstract | Publisher Full Text | Free Full Text 150. van Waart H, Stuiver MM, van Harten WH, et al. : Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. J Clin Oncol. 2015; 33 (17): 1918–27. PubMed Abstract | Publisher Full Text 151. Mundal I, Gråwe RW, Bjørngaard JH, et al. : Psychosocial factors and risk of chronic widespread pain: an 11-year follow-up study--the HUNT study. Pain. 2014; 155 (8): 1555–61. PubMed Abstract | Publisher Full Text 152. Lee KM, Jung D, Hwang H, et al. : Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. J Psychosom Res. 2018; 108 : 14–9. PubMed Abstract | Publisher Full Text 153. Knoerl R, Smith EML, Barton DL, et al. : Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial. J Pain. 2018; 19 (4): 382–94. PubMed Abstract | Publisher Full Text 154. Knoerl R, Barton DL, Holden JE, et al. : Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention. Can Oncol Nurs J. 2018; 28 (3): 178–83. PubMed Abstract | Publisher Full Text | Free Full Text 155. Bruna J, Videla S, Argyriou AA, et al. : Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics. 2018; 15 (1): 178–89. PubMed Abstract | Publisher Full Text | Free Full Text Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 11 Mar 2020 ADD YOUR COMMENT Comment Author details Author details 1 Department of Pain Medicine, The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK Richard Gordon-Williams Roles: Writing – Original Draft Preparation, Writing – Review & Editing Paul Farquhar-Smith Roles: Conceptualization, Supervision, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (1) version 1 Published: 11 Mar 2020, 9:177 https://doi.org/10.12688/f1000research.21625.1 Copyright © 2020 Gordon-Williams R and Farquhar-Smith P. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Gordon-Williams R and Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy [version 1; peer review: 2 approved] . F1000Research 2020, 9 (F1000 Faculty Rev):177 ( https://doi.org/10.12688/f1000research.21625.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Editorial Note on the Review Process Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions . The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. Reviewers who approved this article Irina Vetter , Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Australia Competing interests: No competing interests were declared. (for version 1) Peter M. Grace , Department of Symptom Research, University of Texas MD Anderson Cancer Center, USA Competing interests: No competing interests were declared. (for version 1) Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 11 Mar 2020 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 Version 1 11 Mar 20 Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions . The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations. Irina Vetter , Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Australia Competing interests: No competing interests were declared. View more View less Peter M. Grace , Department of Symptom Research, University of Texas MD Anderson Cancer Center, USA Competing interests: No competing interests were declared. View more View less Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Recent advances in understanding chemotherapy-induced...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-177/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-177/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-177/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Gordon-Williams R and Farquhar-Smith P'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-177/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/9-177", templates : { twitter : "Recent advances in understanding chemotherapy-induced peripheral.... Gordon-Williams R and Farquhar-Smith P, published by " + "@F1000Research" + ", https://f1000research.com/articles/9-177/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/21625/23837") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23837"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "60342": 0, "60343": 3, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "a8002848-1bc8-4dd7-811f-86fdaa662a1f"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });